Galaxis Technology has re-submitted its listing application to the Hong Kong Exchanges and Clearing Limited (HKEX) in recent days. According to data from Frost & Sullivan, based on shipment volume in 2024, the company is the largest supplier in China's Very Narrow Aisle Autonomous Mobile Robot (VNA AMR) sector, with a market share of 19.3%. The prospectus shows that the company recorded an operating revenue of RMB 721 million in 2024, yet it has not achieved profitability during the reporting period, with a significant cumulative loss.
Standard Robots filed a prospectus with the Hong Kong Stock Exchange again, with CITIC Securities and Guotai Junan International as joint sponsors. According to China Insights Consultancy, Standard Robots ranked among China's four major industrial intelligent mobile robot solution providers by sales volume in 2024. For the first nine months of 2025, revenue was RMB 188 million, up 19.7% year-over-year, while the loss for the period was RMB 163 million, representing an expansion compared to the same period last year.
New Shicoh Motor recently filed a listing application with the Hong Kong Stock Exchange, with CICC and Huatai International as joint sponsors. According to a Frost & Sullivan report, the company is China's largest optical image stabilization imaging motor supplier by 2024 revenue, holding a 20.1% market share. The prospectus shows the company achieved 2024 revenue of RMB 1.565 billion and swung to profitability with a net profit of RMB 105 million.
HUTCHMED announced that the Phase III stage of the ESLIM-02 study on its Syk inhibitor sostarlimab for the treatment of warm antibody autoimmune hemolytic anemia has met the primary endpoint, namely sustained hemoglobin response during the treatment period from Week 5 to Week 24. The study targets patients who relapsed or were refractory after previous standard treatments. The company plans to submit a new drug application for this indication to the National Medical Products Administration in the first half of 2026. The Phase III study of sostarlimab for the treatment of immune thrombocytopenia has also achieved positive results, and the company similarly plans to resubmit a new drug application for this indication in the first half of 2026.
Beijing Saimo Technology (2571) announced that it will introduce investors to inject RMB12.0098 million into its subsidiary Zhejiang Saimo in exchange for 49% equity, reducing its stake to 51% while maintaining consolidation. The valuation is approximately RMB12.116 million using the asset-based approach. The transaction constitutes a discloseable transaction under Listing Rules, with the cash portion to be used for R&D and no gain or loss expected to be recognized.
Leadrive Technology recently filed a prospectus with the Hong Kong Stock Exchange for a Main Board listing, with CITIC Securities and Haitong International as joint sponsors. According to Frost & Sullivan, by installed capacity in the first three quarters of 2025, the company's motor controllers ranked eighth, dual-motor controllers ranked third; main drive power bricks ranked second, and power bricks for dual-motor controllers ranked first.
Beijing Roborock Technology has obtained CSRC filing approval for its proposed Hong Kong IPO of up to 33,108,000 shares. The filing is valid for 12 months, requires reporting of material events and post-listing details within 15 working days, and does not represent CSRC's endorsement of investment value or accuracy of materials.
UISEE Technology (Beijing) has obtained CSRC filing approval for its proposed Hong Kong IPO of up to 18,914,150 shares and conversion of 112,264,250 domestic shares held by 41 shareholders into H-shares for circulation. The filing is valid for 12 months, requires reporting of material events and post-listing details within 15 working days, and does not represent CSRC's endorsement of investment value or accuracy of materials.
Beijing Haizhi Technology Group has received CSRC filing approval for its proposed Hong Kong IPO of up to 47,584,600 shares and conversion of 372,400,480 domestic shares held by 40 shareholders into H-shares for circulation. The filing is valid for 12 months, requires reporting of material events and post-listing details within 15 working days, and does not represent CSRC's endorsement of investment value or accuracy of materials.
TwinSolution Technology recently filed for listing on the STAR Market, with Huatai United Securities as the sponsor. According to Yole data and the company's prospectus, its chip testing interface revenue ranked first in mainland China in 2024, with customers including NVIDIA, Apple and other well-known enterprises. Financial data shows the company's 2024 revenue was RMB 331 million, with a three-year compound annual growth rate of 41.54%, though net profit experienced fluctuations. The IPO proceeds are intended primarily for construction of testing interface and probe card production bases, R&D center projects, and working capital supplementation.
On January 5, 2026, SKB BIO-B(06990.HK) issued an announcement stating that its core product sacituzumab govitecan (SAC-TMT) in combination with pembrolizumab for the first-line treatment of specific PD-L1-positive locally advanced or metastatic non-small cell lung cancer has been granted Breakthrough Therapy Designation by the NMPA. This designation supports subsequent conditional approval and priority review applications to accelerate the launch of the indication. Previous relevant Phase 3 clinical trials have shown significant clinical benefits, and the product has accumulated five Breakthrough Therapy Designations, with three indications approved in China and two included in medical insurance. The company and MSD are also advancing multiple clinical studies globally, while the announcement reminds that the development and commercialization of unapproved indications are subject to uncertainties.
EACON Group recently filed another listing application with the Hong Kong Stock Exchange, with Guotai Haitong Securities as the sole sponsor. According to Frost & Sullivan, the company is China's largest provider of autonomous driving solutions for mining areas by number of active mining trucks and 2024 revenue. The prospectus shows 2024 revenue of RMB 986 million and a three-year compound annual growth rate of 305.8%, though net losses continued to widen during the reporting period.
On December 30, 2025, Insilico Medicine, hailed as "the first AI-driven pharmaceutical stock on the Hong Kong stock market" and a strategic investment of the Hong Kong Investment Corporation Limited (HKIC), was listed on the Main Board of the Hong Kong Exchanges and Clearing Limited (HKEX). With a total fundraising of HK$2.277 billion, it has claimed the title of the largest IPO in the biopharmaceutical sector of the Hong Kong stock market in 2025, and its share price delivered an impressive performance on the debut day. It is reported that Biren Technology, another portfolio company of HKIC, is also set to list on the HKEX on January 2, 2026, which indicates that the effectiveness of HKIC’s diversified strategic investment layout continues to unfold.
